Risk and course of SARS-CoV-2 infection in patients treated for hypothyroidism and hyperthyroidism.
作者信息
Brix Thomas H, Hegedüs Laszlo, Hallas Jesper, Lund Lars C
机构信息
Department of Endocrinology, Odense University Hospital, 5000 Odense, Denmark.
Department of Endocrinology, Odense University Hospital, 5000 Odense, Denmark.
出版信息
Lancet Diabetes Endocrinol. 2021 Apr;9(4):197-199. doi: 10.1016/S2213-8587(21)00028-0. Epub 2021 Feb 19.
Abstract
摘要
相似文献
1
Risk and course of SARS-CoV-2 infection in patients treated for hypothyroidism and hyperthyroidism.甲状腺功能减退和甲状腺功能亢进患者感染新型冠状病毒的风险及病程。
Lancet Diabetes Endocrinol. 2021 Apr;9(4):197-199. doi: 10.1016/S2213-8587(21)00028-0. Epub 2021 Feb 19.
2
ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of hyperthyroidism and hypothyroidism.COVID-19 期间的内分泌学：甲状腺功能亢进和甲状腺功能减退症的管理。
Eur J Endocrinol. 2020 Jul;183(1):G33-G39. doi: 10.1530/EJE-20-0445.
3
Impact of Obesity on Outcomes of Patients With Coronavirus Disease 2019 in the United States: A Multicenter Electronic Health Records Network Study.肥胖对美国2019冠状病毒病患者预后的影响：一项多中心电子健康记录网络研究
Gastroenterology. 2020 Dec;159(6):2221-2225.e6. doi: 10.1053/j.gastro.2020.08.028. Epub 2020 Aug 21.
4
Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City.纽约市原发性免疫缺陷患者中 COVID-19 的临床结局和特征。
J Allergy Clin Immunol Pract. 2021 Jan;9(1):490-493.e2. doi: 10.1016/j.jaip.2020.09.052. Epub 2020 Oct 8.
5
Risk of Incident Thyroid Dysfunction in the Post-Acute Phase of COVID-19: A Population-Based Cohort Study in Hong Kong.COVID-19 后急性期甲状腺功能障碍事件风险：香港基于人群的队列研究。
Endocr Pract. 2024 Jun;30(6):528-536. doi: 10.1016/j.eprac.2024.03.389. Epub 2024 Mar 28.
6
Selected thyreology problems during the COVID-19 pandemic. Hypothyroidism and hyperthyroidism - did anything change?在 COVID-19 大流行期间的甲状腺疾病问题。甲状腺功能减退症和甲状腺功能亢进症 - 有什么变化吗？
Endokrynol Pol. 2021;72(2):170-178. doi: 10.5603/EP.a2021.0013.
7
Characteristics and outcomes of patients with cancer and COVID-19: results from a cohort study.癌症合并新型冠状病毒肺炎患者的特征与结局：一项队列研究的结果
Acta Oncol. 2021 Jan;60(1):24-27. doi: 10.1080/0284186X.2020.1863464. Epub 2021 Jan 5.
8
A simple score (Biovid-19) based on biological parameters predicts transfer to intensive care units and death in COVID-19 patients.基于生物学参数的简单评分（Biovid-19）可预测COVID-19患者转入重症监护病房及死亡情况。
Curr Res Transl Med. 2021 May;69(2):103284. doi: 10.1016/j.retram.2021.103284. Epub 2021 Mar 4.
9
Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study.心力衰竭对因 COVID-19 住院患者的临床病程和结局的影响。意大利 Cardio-COVID 多中心研究的结果。
Eur J Heart Fail. 2020 Dec;22(12):2238-2247. doi: 10.1002/ejhf.2052. Epub 2020 Nov 27.
10
The Centrality of Obesity in the Course of Severe COVID-19.肥胖在重症 COVID-19 病程中的核心地位。
Front Endocrinol (Lausanne). 2021 Mar 11;12:620566. doi: 10.3389/fendo.2021.620566. eCollection 2021.
引用本文的文献
1
Thyroid disorders and COVID-19: a comprehensive review of literature.甲状腺疾病与2019冠状病毒病：文献综述
Front Endocrinol (Lausanne). 2025 May 19;16:1535169. doi: 10.3389/fendo.2025.1535169. eCollection 2025.
2
Pregnancy and delivery outcomes in coronavirus disease 2019: a cross-sectional study from a tertiary center.2019年冠状病毒病的妊娠和分娩结局：一项来自三级中心的横断面研究。
Rev Assoc Med Bras (1992). 2025 Mar 17;71(1):e20240842. doi: 10.1590/1806-9282.20240842. eCollection 2025.
3
The Prognostic Properties of Thyroid Disorders, Hypothyroidism, and Hyperthyroidism in Predicting COVID-19 Poor Outcomes: A Systematic Review and Diagnostic Meta-analysis.甲状腺疾病、甲状腺功能减退和甲状腺功能亢进在预测COVID-19不良结局中的预后特性：一项系统评价和诊断性荟萃分析
Indian J Endocrinol Metab. 2022 Nov-Dec;26(6):510-517. doi: 10.4103/ijem.ijem_20_22. Epub 2022 Dec 20.
4
Increased incidence of myxedema coma during the COVID-19 pandemic and in the post pandemic era: a single-center case series.在 COVID-19 大流行期间和大流行后时代，黏液水肿性昏迷的发病率增加：一项单中心病例系列研究。
Intern Emerg Med. 2024 Oct;19(7):1921-1928. doi: 10.1007/s11739-024-03690-9. Epub 2024 Jul 5.
5
Thyroid dysfunction in COVID-19.COVID-19 相关甲状腺功能障碍。
Nat Rev Endocrinol. 2024 Jun;20(6):336-348. doi: 10.1038/s41574-023-00946-w. Epub 2024 Feb 12.
6
From Emergence to Endemicity: A Comprehensive Review of COVID-19.从出现到地方性流行：对新冠病毒病的全面综述
Cureus. 2023 Oct 31;15(10):e48046. doi: 10.7759/cureus.48046. eCollection 2023 Oct.
7
Thyroid Autoimmunity and SARS-CoV-2 Infection.甲状腺自身免疫与2019冠状病毒病感染
J Clin Med. 2023 Oct 5;12(19):6365. doi: 10.3390/jcm12196365.
8
The Comorbidities, Radiographic Findings, Age, and Lymphopenia (CORAL) Tool: A Diagnostic Ally for Emergency Physicians Created for the COVID-19 Crisis and Beyond.合并症、影像学表现、年龄及淋巴细胞减少（CORAL）工具：为应对新冠疫情及后续情况为急诊医生打造的诊断助手。
Cureus. 2023 Jun 27;15(6):e41036. doi: 10.7759/cureus.41036. eCollection 2023 Jun.
9
Free triiodothyronine levels and age influences the metabolic profile and COVID-19 severity parameters in euthyroid and levothyroxine-treated patients.游离三碘甲状腺原氨酸水平和年龄影响甲状腺功能正常和左甲状腺素治疗患者的代谢特征和 COVID-19 严重程度参数。
Front Endocrinol (Lausanne). 2022 Nov 9;13:1025032. doi: 10.3389/fendo.2022.1025032. eCollection 2022.
10
Causal associations between thyroid dysfunction and COVID-19 susceptibility and severity: A bidirectional Mendelian randomization study.甲状腺功能障碍与 COVID-19 易感性和严重程度之间的因果关系：一项双向 Mendelian 随机研究。
Front Endocrinol (Lausanne). 2022 Sep 6;13:961717. doi: 10.3389/fendo.2022.961717. eCollection 2022.
Zotero 插件